<DOC>
	<DOC>NCT02261220</DOC>
	<brief_summary>This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.</brief_summary>
	<brief_title>A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>Male and female subjects 18 years and older Histologic confirmation of advanced solid tumors Subjects must have recurrent/metastatic disease and may have been previously treated in the recurrent/metastatic setting. Any concurrent chemotherapy, immunemediated therapy or biologic or hormonal therapy for cancer treatment Active or prior documented autoimmune disease within the past 2 years Current or prior use of immunosuppressive medication within 14 days with some exceptions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>